Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

  • J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

    Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

  • Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

    Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M1G0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy0PEBp MYjJR|UxRTF|OT6yNQKBkcLz4pEJOU46PSEQvF2= MmPsNlU6PjB{OEK=
KellyCis83 NG\Je2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj5Vno1QCCq M2HiXGlEPTB;MkWxMlAx6oDLwsJihKkyPS55NTFOwG0> M17sWVI2QTZyMkiy
SK-N-AS MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fNTVQ5KGh? MWLJR|UxRTJ{Nz63NQKBkcLz4pEJNlIvOTVizszN MVGyOVk3ODJ6Mh?=
SK-N-ASCis24 NFWzfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq0PEBp NGrkTWNKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>? NF\pRlMzPTl4MEK4Ni=>
CHP-212 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrrOFghcA>? NFnCcHBKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN MnjRNlU6PjB{OEK=
CHP-212Cis100 NGjob|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yzPFQ5KGh? MUfJR|UxRTlwNUZihKnDueLCiUCuPFgh|ryP MWWyOVk3ODJ6Mh?=
U87  MYPGeY5kfGmxbjDBd5NigQ>? NUjuNYg1OTByIN88US=> NF7hXIQzPC15MjDo NUnE[m52cW6mdXPld{BF[1JzIHX4dJJme3Orb36= M4rlO|I2QDB6OE[4
LN229 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELEWGYxNTVyIN88US=> MUfJR|UxRTF4IN88US=> M3HIUFI2PzVyMkez
TR-LN229 M3vsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XURlAuPTBizszN M4KwW2lEPTB;N{eg{txO M3LXUFI2PzVyMkez
U87  NXmzNoJESXCxcITvd4l{KEG|c3H5 MUCw5qCUOjBy4pEJxtVO NITrXVkzPCCq NFLzVGdmdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>? NEfsdYszPTZ6MU[2PC=>
U251MG MXrBdI9xfG:|aYOgRZN{[Xl? MmnyNVAxyqEQvF2= M1HaVVQ5KGh? Mnr0VGJU M1GzZolv\HWlZYOgZZBweHSxc3nz MXuyOVY5ODR4NB?=
U87MG MV;BdI9xfG:|aYOgRZN{[Xl? NHOwPFEyODEEoN88US=> NEjGS4w1QCCq Ml3uVGJU MWrpcoR2[2W|IHHwc5B1d3Orcx?= M4mwflI2PjhyNE[0
U87 NYTjbYVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf2bm02OC1|NUCg{txO NInxOlY1QMLiaNMg NV\iRVd4cW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? NHjh[W8zPTV3NEKyNy=>
U118  NUjseo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr4OVAuOzVyIN88US=> NXTMVGdVPDkEoHlCpC=> MmDSbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> M3L6b|I2PTV2MkKz
U87 M4fLNWZ2dmO2aX;uJGF{e2G7 NEDyZ24zPTBxM{WwJO69VQ>? MkfBOFjDqGkEoB?= MmX4[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm Mn7aNlU2PTR{MkO=
U118  M{H6XmZ2dmO2aX;uJGF{e2G7 NWrvV2dROjVyL{O1NEDPxE1? M3\oZ|Q5yqCqwrC= NVfXdpl4\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn M1LNPFI2PTV2MkKz
U87 NEjiVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTNNlUxNzN3MDFOwG0> M3TEV|Q5yqCqwrC= MkfRbY5kemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJHMh[W6mIFeyM23DqGOxdILlZZRm\CC5aYToJHROYA>? M1;0S|I2PTV2MkKz
A375 M{j2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nscVQ5yqCqwrC= MVrJR|UxRTJ4NTFOwG0> MkXwNlU2OjR3NUK=
A2058 NHfXbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPkV|A5PDkEoHlCpC=> NEjkNodKSzVyPUGyJO69VQ>? M1PJfVI2PTJ2NUWy
M238 M1jvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnTOFjDqGkEoB?= MVLJR|UxRTRyIN88US=> NYrCXppzOjV3MkS1OVI>
M249 M1;ZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHyXpF2PDkEoHlCpC=> NGTtZZBKSzVyPUK1OEDPxE1? MUSyOVUzPDV3Mh?=
M21 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILmZWQ1QMLiaNMg M3LLcWlEPTB;MkKxJO69VQ>? NULqTGY3OjV3MkS1OVI>
U251 MV;DfZRwfG:6aYT5JGF{e2G7 M4PxdFIxKM7:TdMg MYO0POKhcMLi MmDHdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= NGHqcXMzPTR|NEO4NS=>
LN229 MXzDfZRwfG:6aYT5JGF{e2G7 NH;qZZkzOCEQvF5CpC=> MnnHOFjDqGkEoB?= NHP5NpRz\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk NGHJO28zPTR|NEO4NS=>
U373MG-LUC NUO1cFdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TIfFczKGh? NYr3cm5XUUN3ME62NFAh|ryP Mle5NlU1OzF7NUO=
U87  M2C2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\JNlUuOjByIN88US=> NXLnPWRzPDkEoHlCpC=> NFLBRldqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWSyOVQxODd2NR?=
U251 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojINlUuOjByIN88US=> MnrqOFjDqGkEoB?= NVTEZVZVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEDQSVIzPTRyMEe0OS=>
U251 NY\x[lNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvUNVAxNTRyMDFOwG0> NX2yUlFIPzJxOU[gbC=> M{\Tb5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= NYTybXM2OjV|N{WyO|E>
U373 NWr2cGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLTeZZ{OTByLUSwNEDPxE1? MVS3Nk86PiCq MXj0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NVvkTJhHOjV|N{WyO|E>
U343 NGPDbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DpNFExOC12MECg{txO Mo\RO|IwQTZiaB?= MmTYeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi NWe1[4p[OjV|N{WyO|E>
U87MG-luc2 NX\TR2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm0NVAxNTRyMDFOwG0> NIL6dGw4Oi97NjDo NU\O[XpFfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg NXzQdnl1OjV|N{WyO|E>
U87 MlzQSpVv[3Srb36gRZN{[Xl? NYLMN41UOjByIN88US=> Mo\XOFghcA>? NYHBOmJlcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= M3j2UVI2OzN5N{Kx
U251 NUPRboVuTnWwY4Tpc44hSXO|YYm= M3vnUFIxOCEQvF2= MkjoOFghcA>? M4rCUYlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? M3HhNVI2OzN5N{Kx
A172 NUH3TXhkTnWwY4Tpc44hSXO|YYm= M1uxT|IxOCEQvF2= MlTHOFghcA>? MonKbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? NFjWd2UzPTN|N{eyNS=>
U251 NHznZ2dHfW6ldHnvckBCe3OjeR?= M334NVIxOCEQvF2= M1XjflQ5KGh? MV3pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz MYKyOVM{Pzd{MR?=
A172 NFTsNHpHfW6ldHnvckBCe3OjeR?= NYHJdHRDOjByIN88US=> MV20PEBp Mk\pbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MYeyOVM{Pzd{MR?=
U87 NYTBfW9vTnWwY4Tpc44hSXO|YYm= NVvwepVYOjByIN88US=> NF;qWlEzPC95Mj:xNlAhcA>? MV\pcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> NUDrW5p5OjV|M{e3NlE>
U251 Mn7rSpVv[3Srb36gRZN{[Xl? MnvYNlAxKM7:TR?= MljZNlQwPzJxMUKwJIg> NX7KSFh1cW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 NGXwTnAzPTN|N{eyNS=>
A172 Ml\zSpVv[3Srb36gRZN{[Xl? M2HubVIxOCEQvF2= M2\zSVI1Nzd{L{GyNEBp M3f6WIlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MWqyOVM{Pzd{MR?=
SNB19V NFezN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUS3JIQ> MUjEUXNQ NGfDVG9IUTVyPUO1MlfDuTF{IN88US=> M4f6flI2Ojd5NESx
SNB19M Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXjO{Bl MY\EUXNQ Ml:4S2k2OD12NkmuPeKyQDhizszN M2HzVlI2Ojd5NESx
SNB19VR NFjp[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXWZ2g4KGR? MVrEUXNQ NWjQb4kxT0l3ME2yPFAvOsLzMUig{txO MlmzNlUzPzd2NEG=
U373V MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmniO{Bl MYPEUXNQ MUfHTVUxRTZ6LkFCtVMzKM7:TR?= M2nFb|I2Ojd5NESx
U373M NYXLR5psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX6cXg4KGR? MVTEUXNQ NIrXW4lIUTVyPUO2PE44yrF6NjFOwG0> M2fodVI2Ojd5NESx
U373VR MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;LO{Bl M1mzOGROW09? MnXwS2k2OD1{OEiuPOKyOzNizszN MUiyOVI4PzR2MR?=
U87MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrxO{Bl NF7rV5ZFVVOR M3;XVGdKPTB;M{iuN:KyOjBizszN M4D6XFI2Ojd5NESx
HCT116 NF3CflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPmUGI4KGR? NUPhbnJ6TE2VTx?= MVnHTVUxRTV5OT65xtE{OiEQvF2= NIfLTokzPTJ5N{S0NS=>
DLD1 NWTqfVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHoO{Bl M4i0fWROW09? NXzX[HlnT0l3ME21NFEvPMLzOUOg{txO NF\CUpIzPTJ5N{S0NS=>
MRC5 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\0dGw4KGR? MYHEUXNQ MXnHTVUxRTR2OT60xtE5KM7:TR?= Mn3PNlUzPzd2NEG=
SNB19V  Ml3USpVv[3Srb36gRZN{[Xl? NITXfJUyODBizszNxsBVVVp? MXiwMVczKGh? M1nqeYlv[3KnYYPld{DPu0h{QWig[ZhxemW|c3nvckBj\XS5ZXXuJFE3KGGwZDC3NkBp NVziOWhJOjV{N{e0OFE>
T98G  M{\pW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfqOU8yOC9zNTFOwG0> MlfmNlTDqGh? MknwbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= MYWyOVI3Ojl4MR?=
U251  MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrhOU8yOC9zNTFOwG0> MnOzNlTDqGh? MoCybY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= Mn\QNlUzPjJ7NkG=
T98G  MYrGeY5kfGmxbjDBd5NigQ>? MoLUNVUh|ryP M33DPVI1yqCq M4PGcYlv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= MlXNNlUzPjJ7NkG=
U251  M3L0VmZ2dmO2aX;uJGF{e2G7 MXuxOUDPxE1? MYOyOOKhcA>? MUnpcoNz\WG|ZYOgSG5CNW[{YXft[Y51[XSrb36gbY4hVlCnNj3QSHQhfHKnYYTl[EBodGmxbXGgZ4VtdHN? MWGyOVI3Ojl4MR?=
U-87 MG M4K4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu3NkBp NYq4bVBpUUN3ME2wMlk{KG2PwrC= MYSyOVI1PTN|Mh?=
U-118 MG NX;EbYtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PITlczKGh? Mn7wTWM2OD1zLkC1JI1OyqB? NXTXcoxJOjV{NEWzN|I>
U87 NFnLSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnjNlQhcA>? MVfJR|UxRTJ4MD6zOEDPxE4EoB?= NHnLclkzPTF5M{KzNy=>
U87 GSLCs MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiyOEBp MVjJR|UxRTd4Nj6xNUDPxE4EoB?= Mlf5NlUyPzN{M{O=
U87MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYq3NkBp NFjaWmFKSzVyPUG1MlYzPSEQvF5CpC=> NUXIcYh4OjVyNUC5NVU>
U251 M1f5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzxNVAxNTRyMDFOwG0> MmXEOFghcA>? M4PFU2ROW09? MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnnyNlQ3OjN5M{[=
U87 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSxNFAuPDByIN88US=> M3La[VQ5KGh? M{LjUmROW09? NHvmeJBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NEHDV5IzPDZ{M{ezOi=>
MDA-MB-231-br NXywRndET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;BNE0yOCEQvF2= MWK0PEBp M3LRTmROW09? M4HZfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEHneVUzPDZ{M{ezOi=>
HCC-1937 M2nWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTLNE0{ODBizszN Ml2wOFghcA>? MVzEUXNQ NEnlVm5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVzB[5NDOjR4MkO3N|Y>
MDA-MB-231 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KzbFAuPDBizszN MWe0PEBp M1HHd2ROW09? NW[5PVRKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MofGNlQ3OjN5M{[=
MDA-MB-468 M1f2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMVUxOCEQvF2= M1vDSlQ5KGh? NFTGRnRFVVOR MkjzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlT5NlQ3OjN5M{[=
T47D M2X2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[wMVExOCEQvF2= M3zTN|Q5KGh? NFXmZ2NFVVOR NUnBNYpCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXTsVm5kOjR4MkO3N|Y>
MCF7 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPKNE0yODByIN88US=> NHrUfGk1QCCq M1i2cGROW09? NHfN[JpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVuyOFYzOzd|Nh?=
Hs683 NH7IbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jVVFAuOTByMDFOwG0> NEfK[lA6PiCq NFqwe4tKSzVyPUGyPE46KM7:TR?= MYmyOFQ6PTlyNx?=
U87 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnFNE0yODByIN88US=> M2jUd|k3KGh? NGXkPXBKSzVyPUG4MlQ2KM7:TR?= MmL0NlQ1QTV7MEe=
LNZ308 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX0S4V6OC1zMECwJO69VQ>? NX;3S2FMQTZiaB?= NXP5fYJ1UUN3ME2zNlYvPyEQvF2= M{XpOlI1PDl3OUC3
U87 M1mzV2Fxd3C2b4Ppd{BCe3OjeR?= M13VXlExOCEQvF2= NYDMOGtRPDhiaB?= MXfEUXNQ M1ruSolv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= M2OwPVI1PDhzNUi2
U251  Mo[zRZBweHSxc3nzJGF{e2G7 NVvEfZE2OTByIN88US=> MXS0PEBp NXvnfos5TE2VTx?= MVfpcoNz\WG|ZYOgeIhmKGOjc4Dhd4UuOy95IHHjeIl3cXS7 NWXjfHc5OjR2OEG1PFY>
U251 M4noRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzZOlkzPCCq MoXYTWM2OD16Nj6yPgKBkcLz4pEJNU42QCEQvF2= MYmyOFMzPjl3NB?=
U251 NW[2bWlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTVOFghcA>? MljhTWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= NF\T[GszPDN{Nkm1OC=>
U251 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTxO|IhcA>? MXfJR|UxRTd{LkSy5qCKyrIkgJmxMlQ2KM7:TR?= NUj0T|ZEOjR|Mk[5OVQ>
U251 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvoWVM6PiCq MlLyTWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= MlfnNlQ{OjZ7NUS=
T98G MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLKXlUxNTd3MDFOwG0> MnrlO|IwQTZiaB?= MmfMbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVyyOFMzPDB6MB?=
U251-MG M1vyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17mPVAuQDByIN88US=> NWPhcJlXPzJiaB?= MoHjbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEjNOnYzPDB7M{[zNC=>
D54-MG MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTROnBkOC16MECg{txO MmPxO|IhcA>? NULqU41OcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NFzhc2czPDB7M{[zNC=>
SHG-44 M1zaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDTNVAuOjByIN88US=> M3TLclk3KGh? MUfJR|UxRTlwN{OgxtEhOi5zMjFOwG0> NHvuNnEzPDB4NUW2PS=>
U373  M1Sz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqzNJlNOTBvMkCwJO69VQ>? MUS5OkBp MYPJR|UxRTFyLkGzJOKyKDFwMEKg{txO MX[yOFA3PTV4OR?=
HT-29  NHrwdoxHfW6ldHnvckBCe3OjeR?= MYS1NFAh|ryP NHXK[I8zPC92ODDo Mljo[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB? NGToe5YzPDB|OEC2PC=>
PC-3  M2jIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH4NE0zPSEQvF2= MWO0PEBp MVrpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> NHu4bHUzOzd2NkmzOC=>
PC-3  MV\BdI9xfG:|aYOgRZN{[Xl? NVn4[FA1OjVizszN NXHrWIRbPDhiaB?= MVXpcoR2[2W|IHHwc5B1d3OrczD3bIlkcCClYX6gZoUheG:2ZX70bYF1\WRiYomgcJlkd3CnbnW= NI[5RZozOzd2NkmzOC=>
T98G NFPpTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX3OVAuPDByIN88US=> NXfkUZJUOTR2IHi= NHr6d4tqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MXyyN|cyPTR7OR?=
U87-MG NVXGR3NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLTcGZMOTByINM1US=> M1LCNFczKGh? NUXYNnE5cW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= MkXBNlM3QTZ5OEi=
U251-MG NX3QR|QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TiPVExOCEEtV2= NXfn[mZRPzJiaB?= NWPmWIxGcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= MYqyN|Y6Pjd6OB?=
LNT-229 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7JVHlYOy1zMECg{txO MmDsNlQhcA>? NIroT2lqdmirYnn0d{BkdG:wb3flcolkKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M17ocFI{PjZ5NkOy
T98G MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPmelZJOTBvN{CwJO69VQ>? M{TvTlI1KGh? NWHZ[XRjcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHrHS2wzOzZ4N{[zNi=>
U87  MmruSpVv[3Srb36gRZN{[Xl? MYSxNFAhyrWP NIjYeHE{KGh? M{nMNIVt\X[jdHXzJJRp\SCuZY\lcJMhd2ZicFPob|Eh[W6mIIDDbIsz MYCyN|Y3PzR4OR?=
HCT116 M2O4V2Z2dmO2aX;uJGF{e2G7 NUHzUmN5OTByINM1US=> NXf0Npd7OyCq MX7pcoR2[2W|IITo[UBEcGtzIGDoc5NxcG:{eXzheIlwdg>? NHfr[HkzOzZ4N{S2PS=>
HCT3-6 Mn7JSpVv[3Srb36gRZN{[Xl? MYGxNFAhyrWP MmPtN{Bp NV7nUmN1cW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= NGqzVJUzOzZ4N{S2PS=>
U-87  NYPyUHdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\R[nBwOC12MDFOwG0> M1fkVVEzKGR? NWrVRoV4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFrUWIIzOzZ2NUeyPS=>
U-87  NXvU[GFUSXCxcITvd4l{KEG|c3H5 MYKwMVQxKM7:TR?= M3;3[VMwPiCm MVnpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MYGyN|Y1PTd{OR?=
U-87  NIPZe4JHfW6ldHnvckBCe3OjeR?= MoLiNE01OCEQvF2= MUKzM|Yh\A>? NX;U[ZZFcW6mdXPld{BifXSxcHjh[5khcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MYCyN|Y1PTd{OR?=
GB-SCC010 M4jV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;6NlQh\A>? M17tVmlEPTB;MkK2JO69VQ>? MoXyNlM3OTJ5NUW=
GB-SCC026 M4TMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXYUGE1KGR? NHfBXIhKSzVyPUWzMlEh|ryP NE\iOG4zOzZzMke1OS=>
GB-SCC028 M2rFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjDOEBl NXnG[GJsUUN3ME2xOlch|ryP NXXJVFh3OjN4MUK3OVU>
U87 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXTeph6PCCm MVPJR|UxRTR3LkKg{txO NXq4T|NlOjN4MUK3OVU>
U87 stem cell MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XmTlQh\A>? MX;JR|UxRTZ4Lkeg{txO MUWyN|YyOjd3NR?=

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02977780 Recruiting Glioblastoma Dana-Farber Cancer Institute|Eli Lilly and Company|Celgene|Puma Biotechnology Inc.|Accelerate Brain Cancer Cure February 9 2017 Phase 2
NCT00392171 Completed Glioma|Astrocytoma|Oligodendroglioma|Glioblastoma Merck Sharp & Dohme Corp. June 9 2006 Phase 2
NCT00305864 Completed Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma National Cancer Institute (NCI)|Radiation Therapy Oncology Group February 9 2006 Phase 1|Phase 2
NCT00200161 Completed Glioblastoma|Gliomas Memorial Sloan Kettering Cancer Center|Schering-Plough|Columbia University|Dana-Farber Cancer Institute August 9 2005 Phase 2
NCT03528642 Not yet recruiting Anaplastic Astrocytoma IDH-Mutant|Diffuse Astrocytoma IDH-Mutant|IDH1 Gene Mutation|IDH2 Gene Mutation National Cancer Institute (NCI) February 8 2019 Phase 1
NCT03422445 Recruiting Advanced Melanoma Beijing Cancer Hospital January 8 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID